Chronic myeloid leukaemia (in remission) – Diagnostics – Overview of Information and Clinical Research

Diagnosing chronic myeloid leukaemia when the condition is in remission involves specialized blood tests and genetic monitoring to ensure the disease remains under control. Regular follow-up and molecular testing are essential parts of living with CML in remission, even when there are no symptoms present.

Introduction: Who Should Undergo Diagnostics

When chronic myeloid leukaemia is in remission, regular diagnostic testing becomes a lifelong commitment rather than a one-time event. People who have achieved remission through treatment with tyrosine kinase inhibitors (TKIs) – medications that block the abnormal protein causing cancer – need ongoing monitoring to ensure the disease stays controlled. This is true even if you feel completely well and have no symptoms at all.^[1]

You should seek regular diagnostics if you have been diagnosed with chronic myeloid leukaemia and are currently taking medication, have stopped taking medication as part of treatment-free remission, or have achieved what doctors call deep molecular response, meaning tests show very low or undetectable levels of the disease. Even patients who have no detectable signs of leukaemia need frequent blood tests to catch any potential return of the disease early.^[3]

Many people with CML in remission actually discover they have the condition through routine blood work before they ever notice symptoms. Because CML often develops slowly and quietly, you might not feel unwell when the disease is present. This makes regular testing even more important, as it allows doctors to spot changes before symptoms develop.^[2]

The timing of your diagnostic tests depends on your treatment status. If you have recently stopped taking TKIs as part of a treatment break, you will need more frequent monitoring – typically monthly blood tests for the first six months. If your remission remains stable over time, the interval between tests may gradually increase to every two to three months, then eventually to every six months. However, even people who have been in stable remission for years continue to need regular monitoring for life.^[3]

⚠️ Important

Even when you feel completely healthy and have no symptoms, continuing with scheduled blood tests is essential. The majority of people who experience a return of CML do so within the first six months after stopping treatment, and early detection through blood tests allows for immediate restart of medication with excellent chances of regaining remission.^[3]

Diagnostic Methods for CML in Remission

The primary diagnostic tool used to monitor chronic myeloid leukaemia in remission is a blood test called PCR, which stands for polymerase chain reaction. This highly sensitive test looks for the BCR-ABL1 gene, which is the genetic abnormality that causes CML. The BCR-ABL1 gene forms when parts of chromosome 9 and chromosome 22 swap places, creating what scientists call the Philadelphia chromosome. This genetic change produces an abnormal protein that tells bone marrow to make too many white blood cells.^[3]

The PCR blood test can detect extremely small amounts of the BCR-ABL1 gene in your blood, even when there are so few abnormal cells that you would have no symptoms and other tests might not find anything wrong. This sensitivity is crucial for monitoring remission because it allows doctors to spot the disease returning at the earliest possible stage, when treatment can be most effective. The test essentially counts how many copies of the abnormal gene are present in your blood sample.^[11]

When doctors talk about monitoring your CML, they often mention something called molecular response. This refers to how much of the BCR-ABL1 gene can be detected in your blood. A deep molecular response means the test finds very little or no BCR-ABL1 gene, indicating the disease is well controlled. Patients need to maintain this deep molecular response for at least two years before doctors will even consider allowing them to try stopping treatment.^[6]

Your doctor may also perform regular physical examinations to check for signs such as an enlarged spleen, which can occur when CML is active. The spleen is an organ in the upper left part of your abdomen, and it can become swollen if too many abnormal blood cells accumulate there. By feeling your abdomen during an examination, doctors can detect whether your spleen has grown larger than normal.^[1]

Complete blood counts are another routine diagnostic test used during remission monitoring. These tests measure the numbers of different types of blood cells in your body, including red blood cells, white blood cells, and platelets. While PCR testing looks specifically for the genetic abnormality, complete blood counts give doctors a broader picture of your blood health and can reveal changes that might indicate the disease is becoming active again.^[2]

If your PCR test shows the BCR-ABL1 gene is detectable again after a period when it could not be found, this signals that your CML may be returning. This does not necessarily mean you are in immediate danger, but it does mean your doctors will recommend restarting treatment with TKIs. The good news is that when treatment is restarted promptly based on these early warning signs from blood tests, the vast majority of people – studies show almost 100% – achieve remission again.^[6]

Diagnostics for Clinical Trial Qualification

Clinical trials studying treatment-free remission in CML have established specific diagnostic criteria that patients must meet to be eligible for safely stopping their medication. Understanding these criteria helps explain why such careful testing is necessary and what doctors look for when evaluating whether someone can attempt a treatment break.^[4]

To qualify for most treatment-free remission trials or programs, patients must have taken TKIs continuously for at least three to five years. This long treatment period helps ensure the disease has been thoroughly suppressed. Diagnostic tests must show that you have achieved and maintained deep molecular response for at least two years. Deep molecular response, as measured by PCR testing, means the BCR-ABL1 gene is either undetectable or present at extremely low levels in your blood.^[3]

Genetic testing plays an important role in determining eligibility for treatment-free remission. Doctors perform tests to look for additional chromosomal abnormalities beyond the Philadelphia chromosome. If you have extra genetic changes, this may affect whether stopping treatment is safe for you. Your medical history also matters – patients who have previously experienced accelerated or blast phase leukaemia, which are more aggressive forms of the disease, are typically not considered good candidates for treatment breaks.^[3]

Before considering a treatment break, your healthcare team needs to confirm that your local hospital or clinic has a laboratory capable of performing the specialized PCR blood tests you will need during monitoring. These tests require specific equipment and expertise, and not all facilities can provide them. This diagnostic capability is essential because frequent, reliable testing is the safety net that makes treatment-free remission possible.^[3]

Your healthcare team will also assess your understanding and commitment to the monitoring schedule. Successful participation in treatment-free remission requires that you are willing and able to attend all scheduled blood test appointments, which are frequent especially in the first year after stopping medication. Missing tests could mean a returning disease goes undetected for too long, potentially making it harder to treat effectively.^[3]

⚠️ Important

Clinical trials have shown that treatment-free remission is safest when strict monitoring schedules are followed. If CML returns, it most commonly happens within the first six months after stopping treatment, which is why testing is most frequent during this period. The ability to detect disease return early through these diagnostic tests is what makes treatment-free remission a safe option for eligible patients.^[4]

During treatment-free remission monitoring, the schedule of PCR testing is carefully structured. In the first six months after stopping TKIs, you will typically need monthly blood tests. If these tests continue to show no detectable disease, the frequency may reduce to tests every six to eight weeks for the next six months. After the first year, if you remain in remission, testing may occur every two to three months. This gradual reduction in testing frequency reflects the lower risk of disease return over time, though monitoring continues indefinitely.^[3]

Some patients experience what doctors call withdrawal syndrome when they stop taking TKIs. This can include symptoms such as aching muscles and joints or generally feeling unwell. While these symptoms are usually mild and temporary, it is important to distinguish them from signs of disease return through diagnostic testing. Blood tests allow your doctor to confirm that symptoms are simply withdrawal effects rather than CML becoming active again.^[3]

Research has shown that approximately half of patients who attempt treatment-free remission are able to maintain their remission without medication for extended periods, while the other half eventually need to restart treatment based on diagnostic test results. Importantly, restarting treatment when tests indicate it is necessary leads to successful remission again in nearly all cases, demonstrating that this carefully monitored approach is safe when proper diagnostic protocols are followed.^[4]

Prognosis and Survival Rate

Prognosis

The outlook for people with chronic myeloid leukaemia in remission is remarkably positive compared to past decades. In the 1970s, only 22% of people with CML survived five years after diagnosis. Today, thanks to tyrosine kinase inhibitors, the five-year survival rate has improved dramatically to 71%. Many people with CML who maintain good response to treatment can expect to have a life expectancy close to that of the general population.^[1]

For people diagnosed in the chronic phase of CML, which represents the majority of cases, the prognosis is particularly good. Most people receive their diagnosis during this early, slower-progressing phase, which greatly increases the likelihood of successful long-term disease control. Patients who achieve deep molecular remission and maintain it for extended periods have excellent outcomes, with many able to consider treatment-free remission as an option.^[1]

Several factors influence individual prognosis. People diagnosed in the accelerated or blast phase, where the disease is more aggressive, may face more challenges in achieving and maintaining remission. The presence of additional chromosomal abnormalities beyond the Philadelphia chromosome can also affect outcomes. However, even when CML returns after a treatment break, restarting medication promptly based on monitoring tests leads to successful remission again in the vast majority of cases.^[2]

The concept of treatment-free remission has introduced a new dimension to prognosis. Research shows that about half of patients who meet the strict criteria for stopping treatment are able to remain in remission without medication for years. For those whose disease returns, the ability to detect it early through regular blood tests and restart treatment successfully means the overall prognosis remains favorable. Some patients have remained in treatment-free remission for many years with no signs of disease return.^[4]

Survival rate

The survival rate for CML has undergone a remarkable transformation since the introduction of targeted therapy. Before tyrosine kinase inhibitors became available, CML was a life-threatening illness, with only about one in five people surviving more than ten years. The disease would typically progress from the chronic phase to more aggressive forms within three to four years without effective treatment.^[2]

Current statistics show that the overall survival of patients with CML treated with tyrosine kinase inhibitors is very close to that of the healthy population. The five-year survival rate improved from 22% in the 1970s to 71% by 2017, and this trend has continued to improve. Eight-year overall survival rates have reached 87% for patients treated with first-generation TKIs like imatinib.^[1]^[4]

Most people with CML today can expect to live for many years while managing the disease as a chronic condition. The key to these improved survival rates is early detection, appropriate treatment, and consistent monitoring. People who maintain deep molecular responses through treatment have survival rates approaching those of people without CML. The advent of multiple generations of TKIs has provided options for nearly all patients, even those who do not respond well to initial treatments.^[2]

For patients in treatment-free remission, survival outcomes remain excellent as long as they maintain regular diagnostic monitoring. The ability to detect disease return early and restart treatment when needed preserves the favorable survival statistics. Even after years of treatment-free remission, patients who eventually need to resume medication typically achieve good responses, contributing to the overall high survival rates seen in modern CML management.^[4]

#1 Clinical Trials Search in Europe